EPISODE · Apr 15, 2026 · 31 MIN
Role of AKT and PI3K Inhibitors in Patients With HR-Positive Breast Cancers: Experts Share Their Thoughts on Current Practice and Future Opportunities
from Decera Clinical Education Oncology Podcast · host Nadia Harbeck MD, Francois-Clement Bidard MD PhD
Podcast with global experts discussing the role of AKT and PI3K inhibitors in patients with resistance to endocrine therapy in the adjuvant or metastatic disease settings following current guidelines, indications, and best clinical practices. Presenters: Nadia Harbeck, MD Breast Cancer Director Department of OB&GYN and Comprehensive Cancer Center Munich LMU University Hospital Munich, Germany Francois-Clement Bidard, MD, PhD Breast Medical Oncology Institut Curie & University of Versailles Paris, France Link to full program:https://bit.ly/4cFd0Xj Get access to all our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Embed this episode
What this episode covers
Listen to this podcast with Nadia Harbeck, MD, and Francois-Clement Bidard, MD, PhD, sharing their thoughts on the role of AKT and PI3K inhibitors in patients with primary or secondary endocrine-resistant breast cancers.
Ready to play
Role of AKT and PI3K Inhibitors in Patients With HR-Positive Breast Cancers: Experts Share Their Thoughts on Current Practice and Future Opportunities
No transcript for this episode yet
Similar Episodes
No similar episodes found.